How common is childhood myasthenia? The UK incidence and prevalence of autoimmune and congenital myasthenia

Archives of Disease in Childhood

Volumn 99, Issue 6, 2014, Pages 539-542

  Parr, Jeremy Ross ^a,b   Andrew, Morag Jane ^b   Finnis, Maria ^b   Beeson, David ^c   Vincent, Angela ^c   Jayawant, Sandeep ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR; MUSCLE SPECIFIC KINASE RECEPTOR ANTIBODY; PROTEIN ANTIBODY; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; MATERNAL ANTIBODY; CHOLINERGIC RECEPTOR ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHILDHOOD DISEASE; CHRNE GENE; CONGENITAL MYASTHENIC SYNDROME; DOK7 GENE; FEMALE; GENE; GENE MUTATION; GENETIC SCREENING; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNOASSAY; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; NEWBORN PERIOD; PREVALENCE; PRIORITY JOURNAL; RAPSN GENE; UNITED KINGDOM; CHILDHOOD MYASTHENIA; MYASTHENIA; PASSIVE IMMUNIZATION; AGE DISTRIBUTION; AUTOIMMUNE DISEASE; AUTOIMMUNE MYASTHENIA; CONTROLLED STUDY; INFANT; LABORATORY TEST; NEWBORN; SEX DIFFERENCE;

EPIDEMIOLOGY; NEUROLOGY; NEUROMUSCULAR;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; GREAT BRITAIN; HUMANS; INCIDENCE; INFANT; MALE; MUTATION; MYASTHENIC SYNDROMES, CONGENITAL; PREVALENCE;

EID: 84901052383     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2013-304788     Document Type: Article

References (15)

1. Damian MS, Ben-Shlomo Y, Howard R, et al. The effect of secular trends and specialist neurocritical care on mortality for patients with intracerebral haemorrhage, myasthenia gravis and Guillain-Barre syndrome admitted to critical care: an analysis of the Intensive Care National Audit & Research Centre (ICNARC) national United Kingdom database. Intensive Care Med 2013;39:1405-12.
2. Parr J, Jayawant S, Buckley C, et al. Childhood autoimmune myasthenia. In: Dale R, Vincent A, eds. Inflammatory and autoimmune disorders of the nervous system in children. 1st edn. London: Mac Keith Press, 2010:388-405.
3. Finnis MF, Jayawant S. Juvenile myasthenia gravis: a paediatric perspective. Autoimmune Dis 2011;2011:404101.
4. Verschuuren JJ, Palace J, Gilhus NE. Clinical aspects of myasthenia explained. Autoimmunity 2010;43:344-52.
5. Belaya K, Finlayson S, Slater CR, et al. Mutations in DPAGT1 cause a limb-girdle congenital myasthenic syndrome with tubular aggregates. Am J Hum Genet 2012;91:193-201.
6. Carr AS, Cardwell CR, McCarron PO, et al. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol 2010;10:46.
7. Evoli A, Batocchi AP, Bartoccioni E, et al. Juvenile myasthenia gravis with prepubertal onset. Neuromuscul Disord 1998;8:561-7. (Pubitemid 28555738)
8. Ashraf VV, Taly AB, Veerendrakumar M, et al. Myasthenia gravis in children: a longitudinal study. Acta Neurol Scand 2006;114:119-23. (Pubitemid 44034260)
9. Heckmann JM, Hansen P, Van TR, et al. The characteristics of juvenile myasthenia gravis among South Africans. S Afr Med J 2012;102:532-6.
10. Pakzad Z, Aziz T, Oger J. Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada. Neurology 2011;76:1526-8.
11. Vincent A, Waters P, Leite MI, et al. Antibodies identi fied by cell-based assays in myasthenia gravis and associated diseases. Ann N Y Acad Sci 2012;1274:92-8.
12. Leite MI, Jacob S, Viegas S, et al. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 2008;131(Pt 7):1940-52. (Pubitemid 351957451)
13. Vogt J, Morgan NV, Rehal P, et al. CHRNG genotype-phenotype correlations in the multiple pterygium syndromes. J Med Genet 2012;49:21-6.
14. Haliloglu G, Anlar B, Aysun S, et al. Gender prevalence in childhood multiple sclerosis and myasthenia gravis. J Child Neurol 2002;17:390-2. (Pubitemid 34919132)
15. Lane RJ, Roncaroli F, Charles P, et al. Acetylcholine receptor antibodies in patients with genetic myopathies: clinical and biological significance. Neuromuscul Disord 2012;22:122-8.